Dyadic International (NASDAQ:DYAI) Shares Pass Below 50 Day Moving Average – Should You Sell?

Dyadic International Inc. (NASDAQ:DYAI)’s share price crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.89 and traded as low as $0.79. Dyadic International shares last traded at $0.8115, with a volume of 131,094 shares.

Analyst Ratings Changes

DYAI has been the topic of several recent analyst reports. HC Wainwright started coverage on shares of Dyadic International in a research note on Thursday, October 23rd. They set a “buy” rating and a $3.00 target price on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a report on Monday, December 29th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $3.00.

Dyadic International Price Performance

The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 1.92. The stock’s 50 day moving average price is $0.89 and its two-hundred day moving average price is $0.96. The firm has a market capitalization of $29.37 million, a price-to-earnings ratio of -3.38 and a beta of 1.27.

Institutional Investors Weigh In On Dyadic International

Several hedge funds have recently modified their holdings of the business. Geode Capital Management LLC increased its position in Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 36,266 shares during the period. Marathon Capital Management boosted its holdings in Dyadic International by 142.9% in the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 50,000 shares during the period. Apis Capital Advisors LLC acquired a new stake in Dyadic International in the 3rd quarter worth $1,817,000. Landscape Capital Management L.L.C. bought a new position in shares of Dyadic International during the 3rd quarter worth about $190,000. Finally, Truist Financial Corp increased its holdings in shares of Dyadic International by 30.5% during the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock worth $385,000 after purchasing an additional 76,200 shares during the period. 27.95% of the stock is owned by institutional investors.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.